Shares of PDS Biotechnology (PDSB) have been struggling lately and have lost 11.2% over the past week. However, a hammer ...

PDS Biotechnology (NASDAQ:PDSB), a clinical-stage immunotherapy company focused on innovative oncology and infectious disease solutions, released its second quarter results on August 13, 2025, for the ...

PDS Biotechnology (PDSB) has been on a downward spiral lately with significant selling pressure. After declining 35.7% over the past four weeks, the stock looks well positioned for a trend reversal as ...

View PDS Biotechnology Corp. PDSB stock quote prices, financial information, real-time forecasts, and company news from CNN.

Fintel reports that on November 25, 2025, B. Riley Securities maintained coverage of PDS Biotechnology (NasdaqCM:PDSB) with a Buy recommendation. Analyst Price Forecast Suggests 1,000.25% Upside As of ...

The fourth quarter of 2025 capped a period of important progress for PDS Biotech, marked by meaningful advances across our clinical programs, along with financial discipline and expansion of our ...

This period saw the company reduce total operating expenses by 12.6% (GAAP), driven mainly by lower personnel and professional service fees. Research and development, or R&D, costs (GAAP) decreased ...